Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system.
Additional information
-- Roche Health Kiosk, Influenza: http://www.health-kiosk.ch/start_grip.htm
-- About Tamiflu: http://www.roche.com/med_mbtamiflu05e.pd...
-- About influenza: http://www.roche.com/med_mbinfluenza05e....
-- WHO: Global influenza programme: http://www.who.int/csr/disease/influenza...
-- WHO: Avian flu: http://www.who.int/mediacentre/factsheet...
References
---------------------------------
(1) Antivirals and therapeutics session, X International symposium on Respiratory Viral infections, Singapore, Sunday 2nd March 2008
(2) World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. 28 February 2008 http://www.who.int/csr/disease/avian_inf...
(3) Sedyaningsih ER. The Indonesian Experience, X International symposium on Respiratory Viral infections, Singapore, Sunday 2nd March 2008
(4) Wertheim HFI. The recent Vietnamese Experience, X International symposium on Respiratory Viral infections, Singapore, Sunday 2nd March 2008
(5) Govorkova E. Influenza Antivirals in H5N1 Disease, Animal Model, X International symposium on Respiratory Viral infections, Singapore, Sunday 2nd March 2008
(6) Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on Avian Influenza A (H5N1) Virus Infection in Humans. N Engl J Med 358;3
(7) de Jong MD, Thanh TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667-72
(8) Saad MD, Boynton BR, Earhart KC, et al. Detection of oseltamivir resistance mutation N294S in humans with influenza A H5N1. In: Program and abstracts of the Options for the Control of Influenza Conference, Toronto, June 17-23, 2007:228. abstract.
(9) Hurt AC. et al. Susceptibility of highly pathogenic (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Research 73 (2007) 228-231
(10) World Health Organization. Influenza A (H1N1) virus resistance to oseltamivir - Last quarter 2007 to 28 February 2008. 28 February 2008.
http://www.who.int/csr/disease/influenza...
(11) World Health Organization. WHO/ECDC frequently asked questions for Oseltamivir Resistance. Last updated 15 February 2008.
F. Hoffmann-La Roche AG, CH-4070 Basel, International Communications Manager, Helen Walicka, Tel. +41-(0)79-263-9701, http://www.roche.com
